FDA Issues Final REMS

FDA Issues Final REMS

The long-awaited final version of the FDA’s opioid risk evaluation and mitigation strategy includes an educational “blueprint,” new opportunities for continuing medical education providers.

The Food and Drug Administration has released the final form of its Risk Evaluation and Mitigation Strategies, or REMS, for extended-release and long-acting opioids. The 20 companies that manufacture these drugs, whose misuse and abuse of ER/LA opioids has become so widespread that related overdoses, addiction, and deaths now constitute a public health crisis, are now required to educate

Register to view the full article

Register for MeetingsNet.com and gain access to premium content including the CMI 25 Listing, our monthly digital edition, the MeetingsNet app, live and on-demand webinars, and much more.

Already a member? .

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish